Trial Information

Summary: A Phase II study to evaluate safety and efficacy of an investigational drug in patients with Relapsing-Remitting Multiple Sclerosis (MS). This drug is involved in the blockage of the T cells in the immune system, which is involved in MS. This is a 10-month, double-blind, placebo controlled research study with 9 intravenous infusions.

Study Description

This Phase II research study will evaluate the safety and efficacy of an investigational drug in patients with Relapsing Remitting Multiple Sclerosis (MS).

This drug is being used for the first time in MS. Studies suggest that this drug is involved in the blockage of the T cells in the immune system, which is involved in MS. This is a 10-month double-blind placebo-controlled research study with 9 intravenous (into the vein) infusions.

Study Criteria

Female and male volunteers 18-55 years old with Relapsing Remitting MS who have been unable to tolerate or have never been immunomodulating therapy to treat the MS (For example: interferons (Avonex, Betaseron) glatiramer acetate (Copaxone), mitoxantrone).

Cannot participate if you are pregnant or planning a pregnancy and must practice 2 forms of birth control. Volunteers cannot have had an exacerbation within 2 months of enrollment. Must have had one relapse over the past 2 years. Tests and evaluations will be paid for by the study. Must meet additional eligibility criteria.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.